AUROPHARMA - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 4.0
✅ Positive
Aurobindo Pharma demonstrated strong earnings growth over the past two quarters, with PAT increasing by 69.6% Qtr on Qtr and reporting a healthy profit of 692 Cr in the latest quarter. The company also secured a significant licensing agreement with Merck for a generic HIV drug, indicating potential future revenue streams.
⚠️ Limitation
While the company exhibits positive momentum, the stock is trading at a relatively high P/E ratio of 37.2 and PEG ratio of 1.44, suggesting it may be overvalued. Increased DII holding decrease might signal some investor concern.
📉 Company Negative News
The scheduled AGM via VC suggests potential operational changes or governance concerns, although no specific details were provided.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is generally considered stable and resilient, driven by ongoing demand for generic drugs and innovative therapies. Aurobindo Pharma operates within this sector, benefiting from the increasing global healthcare expenditure and growing demand for affordable medicines.
🧾 Conclusion
A buy entry could be established around 1,550 ₹, utilizing the current price as a base. Initial profit-taking exit levels should be set at 1,600 ₹ (a 3.8% gain) and 1,585 ₹ (a 2% gain). Overall, considering volume and momentum, this stock appears to offer a good opportunity for intraday trading with moderate risk tolerance.